Coeptis Therapeutics Amends Merger Proxy to Correct Post-Merger Shareholder Ownership Details

summarizeSummary

Coeptis Therapeutics Holdings, Inc. filed a supplement to its January 5, 2026 proxy statement, correcting typographical errors in the post-merger principal stockholder table for the reverse merger with Z Squared Inc.

check_boxKey Events

• Corrects Post-Merger Ownership Data

  The filing amends the proxy statement dated January 5, 2026, to correct typographical errors in the "Principal Stockholders of Proposed Combined Company" table.

• Clarifies Major Shareholder Stakes

  The correction impacts the reported beneficial ownership percentages, including BSG Series CM at 73.37% and the executive officers and directors as a group at 2.79% post-merger.

• Relates to Prior Reverse Merger Disclosure

  This supplement follows the 424B3 filing on January 5, 2026, which announced the reverse merger with Z Squared Inc., a cryptocurrency mining firm.

auto_awesomeAnalysis

This DEFA14A filing is important as it provides corrected and clarified information regarding the post-merger ownership structure of Coeptis Therapeutics Holdings, Inc. following its reverse merger with Z Squared Inc. While described as "typographical errors," changes to the principal stockholder table, especially for a combined entity, are material for investors assessing control and potential dilution. The correction ensures accurate disclosure of who will hold significant stakes in the company after the merger, which is a critical detail for shareholders voting on the transaction.